Goodwin Procter·PHARMA / BIOTECH
Genentech, Biocon Settle Pertuzumab BPCIA Litigation in New Jersey
A New Jersey federal court dismissed without prejudice all claims in Genentech and Roche's BPCIA suit against Biocon over its pertuzumab biosimilar on October 14, 2026, ending the dispute before any merits ruling.
pertuzumabbiosimilarbpciagenentechbiocondismissal-without-prejudicenew-jersey
Read the original firm alert → Thursday, October 22, 2026